RxDoctor Payments Data

Alison Savage, MD

Hematology & Oncology · Medford, ORNPI 1962469585

Payments from drug & device makers

What this record shows

This record is dominated by education: $534 of the $730 with a category attached, or 73.2%. 10 manufacturers reported payments, led by Astellas Pharma US Inc at 27.1% of the total. Reporting peaked in 2021 at $404 and has fallen 89.9% since, to $41 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OR, where the typical reported total is $847.

$730in general payments, 2019–2025

Across 14 payments — averaging $52.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$198
  • Amgen$135
  • Incyte Corporation$100
  • Pharmacyclics LLC, An Abbvie Company$99
  • Genentech USA, Inc.$95
  • Merck$27
  • plus $77 from 4 others
$353,971in research payments, 2019–2025

Across 106 payments — averaging $3339.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$160K
  • Pfizer$73K
  • Takeda Pharmaceuticals U.S.A., Inc.$50K
  • AstraZeneca$25K
  • Eli Lilly$21K
  • Regeneron$20K
  • plus $6K from 2 others

What the payments were for

  • Food & beverage$19627%
  • Education$53473%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$730 in reported general payments places this provider in the 45th percentile of 112 hematology & oncology providers in Oregon.

See all hematology & oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$108,983
Medicare patients
363
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate56$707,802
OrserduElacestrant Hcl18$505,252
JakafiRuxolitinib Phosphate44$460,771
Lenalidomide44$450,500
XtandiEnzalutamide24$328,925
BrukinsaZanubrutinib18$249,459
PomalystPomalidomide11$241,476
OdomzoSonidegib Phosphate17$227,890
TagrissoOsimertinib Mesylate13$221,156
IbrancePalbociclib15$218,950
ImbruvicaIbrutinib19$214,838
EliquisApixaban29$31,845
XareltoRivaroxaban14$17,505
Anastrozole215$5,420
Exemestane27$4,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$100$460,77144 claims
Astellas Pharma US IncXtandi$198$328,92524 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$99$214,83819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 112 hematology & oncology providers in Oregon.

Other hematology & oncology in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →